Reata Pharmaceuticals Inc Stock
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel therapeutics for patients with severe and life-threatening diseases. The company's primary business areas include drug discovery and development in fields such as cardiovascular, fibrotic, mitochondrial, and neurodegenerative diseases. With a strong emphasis on research and innovation, Reata Pharmaceuticals seeks to deliver cutting-edge treatments that address unmet medical needs, improve patient outcomes, and significantly impact the lives of those suffering from rare and debilitating conditions. As a publicly traded company, Reata Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol "RETA."
Pros and Cons of Reata Pharmaceuticals Inc in the next few years
Pros
Cons
Performance of Reata Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Reata Pharmaceuticals Inc | - | - | - | - | - | - | - |
| Immunic Inc. | -2.270% | 4.139% | -0.323% | -4.861% | -13.776% | -90.434% | - |
| NanoViricides Inc. | -8.620% | -6.452% | 7.407% | 10.476% | 22.751% | -67.973% | -74.438% |
| Ocuphire Pharma Inc. | 1.320% | -2.123% | -5.467% | -65.879% | -40.608% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Reata Pharms, a company operating within the Biotechnology & Medical Research industry, presents a mix of both encouraging and concerning financial figures. Their financial statements reveal a rapid growth in assets and research & development (R&D) expenditures, which is indicative of a company investing in its future. However, Reata Pharms' increasing net losses and negative stockholder equity may raise concerns among investors. The following detailed analysis explores the pros and cons of the company's financial position.
*Pros: *
Growing total assets: Reata Pharms has seen growth in its total assets over the years, increasing from 857,598,000 USD in 2020 to 735,016,000 USD in 2021, and finally reaching 514,491,000 USD as of 2022-12-31. This growth reflects a company that continues to create value for its stakeholders.
Comments
